Albumin-free factor VIII formulations
View Patent ↗A Factor VIII composition formulated without albumin, comprising the following formulation excipients in addition to Factor VIII: 4% to 10% of a bulking agent selected from the group consisting of mannitol, glycine and alanine; 1% to 4% of a stabilizing agent selected from the group consisting of sucrose, trehalose, raffinose, and arginine; 1 mM to 5 mM calcium salt; 100 mM to 300 mM NaCl; and a buffering agent for maintaining a pH of approximately between 6 and 8. Alternatively, the formulation can comprise 2% to 6% hydroxyethyl starch; 1% to 4% of a stabilizing agent selected from the group consisting of sucrose, trehalose, raffinose, and arginine; 1 mM to 5 mM calcium salt; 100 mM to 300 mM NaCl; and a buffering agent for maintaining a pH of approximately between 6 and 8. In a further embodiment, the formulation can comprise: 300 mM to 500 mM NaCl; 1% to 4% of a stabilizing agent selected from the group consisting of sucrose, trehalose, raffinose, and arginine; 1 mM to 5 mM calcium salt; and a buffering agent.
1. A lyophilized Factor VIII composition without albumin, said composition made by lyophilizing an aqueous solution comprising:
Factor VIII;
4% to 10% of a bulking agent selected from the group consisting of mannitol, glycine and alanine;
1% to 4% of a stabilizing agent selected from the group consisting of sucrose, trehalose, raffinose, and arginine;
a calcium salt;
100 mM to 300 mM sodium chloride (NaCl); and
a buffering agent.
2. The lyophilized Factor VIII composition of claim 1 , wherein said lyophilizing comprises:
(a) freezing the aqueous solution at a temperature of less than −35° C.;
(b) annealing the aqueous solution at −23° C.;
(c) lowering the temperature of the aqueous solution to between −45° C. and −55° C.;
(d) annealing the aqueous solution at −33° C.; and then
(e) freeze-drying the aqueous solution.
3. The lyophilized Factor VIII composition of claim 1 , wherein said bulking agent is present in an amount of about 8%.
4. The lyophilized Factor VIII composition of claim 1 , wherein said bulking agent is mannitol.
5. The lyophilized Factor VIII composition of claim 1 , wherein said bulking agent is glycine.
6. The lyophilized Factor VIII composition of claim 1 , wherein said stabilizing agent is present in an amount of about 2%.
7. The lyophilized Factor VIII composition of claim 1 , wherein said stabilizing agent is sucrose.
8. The lyophilized Factor VIII composition of claim 1 , wherein said stabilizing agent is arginine.
9. The lyophilized Factor VIII composition of claim 1 , wherein said stabilizing agent is trehalose.
10. The lyophilized Factor VIII composition of claim 1 , wherein said calcium salt is calcium chloride.
11. The lyophilized Factor VIII composition of claim 1 , wherein said NaCl is present in an amount of from 150 mM to 250 mM.
12. The lyophilized Factor VIII composition of claim 1 , wherein said calcium salt is present in an amount of from 1 mM to 5 mM.
13. The lyophilized Factor VIII composition of claim 12 , wherein said NaCl is present in an amount of about 225 mM.
14. The lyophilized Factor VIII composition of claim 1 , wherein said buffering agent comprises between 10 mM and 50 mM histidine.
15. The lyophilized Factor VIII composition of claim 14 , wherein the histidine is present in an amount of about 25 mM.
16. The lyophilized Factor VIII composition of claim 1 , wherein said buffering agent is selected from the group consisting of tris-(hydroxymethyl)-aminomethane, 1,3-bis-[tris-(hydroxy-methyl)methylamino]-propane, histidine, piperazine-N,N′-bis-(2-ethanesulfonic acid), 3-(N-morpholino) propanesulfonic acid, N-2-hydroxyethyl-piperazine-N′-2-ethanesulfonic acid, 2-(N-morpholino) ethanesulfonic acid and N-2-acetamido-2-aminoethanesulfonic acid.
17. The lyophilized Factor VIII composition of claim 16 , wherein said buffering agent comprises tris-(hydroxymethyl)-aminomethane.
18. The lyophilized Factor VIII composition of claim 17 , wherein the tris-(hydroxymethyl)-aminomethane is present in an amount of about 20 mM.
19. The lyophilized Factor VIII composition of claim 1 , further comprising a surfactant.
20. The lyophilized Factor VIII composition of claim 19 , wherein said surfactant is present in an amount of about 0.03%.
21. The lyophilized Factor VIII composition of claim 19 , wherein said surfactant is selected from the group consisting of polyoxyethylene (20) sorbitan fatty acid ester, polyoxyethylene (80) sorbitan fatty acid ester, polyoxyalkylene ether, and polyoxyethylene 35 lauryl ether.
22. The lyophilized Factor VIII composition of claim 21 , wherein said surfactant is polyoxyethylene (80) sorbitan fatty acid ester, and wherein said polyoxyethylene (80) sorbitan fatty acid ester is present in an amount of between 0.02% and 0.1%.
23. The lyophilized Factor VIII composition of claim 1 , further comprising an antioxidant.
24. The lyophilized Factor VIII composition of claim 23 , wherein said antioxidant is glutathione.
25. The lyophilized Factor VIII composition of claim 24 , wherein said glutathione is present in an amount of between 0.05 mg/ml and 1.0 mg/ml.
26. The lyophilized Factor VIII composition of claim 1 in combination with a diluent.
27. The lyophilized Factor VIII composition of claim 26 , wherein the diluent is present in 2 ml.
28. The lyophilized Factor VIII composition of claim 26 , wherein the diluent is present in 5 ml.
29. The lyophilized Factor VIII composition of claim 1 , wherein said lyophilizing comprises:
(a) freezing the aqueous solution at a temperature of less than −35° C.;
(b) annealing the aqueous solution at between −30° C. and −19° C.;
(c) lowering the temperature of the aqueous solution to between −45° C. and −55° C.;
(d) annealing the aqueous solution at between −30° C. and −39° C.; and then
(e) freeze-drying the aqueous solution.
30. The lyophilized Factor VIII composition of claim 29 , wherein the temperature in step (a) is about −40° C.
31. The lyophilized Factor VIII composition of claim 29 , wherein the temperature in step (b) is about −26° C.
32. The lyophilized Factor VIII composition of claim 29 , wherein the temperature in step (b) is about −23° C.
33. The lyophilized Factor VIII composition of claim 29 , wherein the temperature in step (d) is about −36° C.
34. The lyophilized Factor VIII composition of claim 29 , wherein the temperature in step (d) is about −33° C.
35. A lyophilized Factor VIII composition without albumin, said composition made by lyophilizing an aqueous solution comprising:
Factor VIII;
4% to 10% mannitol;
1% to 4% trehalose;
and 100 mM to 300 mM NaCl.
36. The lyophilized Factor VIII composition of claim 35 , wherein said lyophilizing comprises:
(a) freezing the aqueous solution at a temperature of less than −35° C.;
(b) annealing the aqueous solution at between −30° C. and −19° C.;
(c) lowering the temperature of the aqueous solution to between −45° C. and −55° C.;
(d) annealing the aqueous solution at between −30° C. and −39° C.; and then
(e) freeze-drying the aqueous solution.
37. The lyophilized Factor VIII composition of claim 35 , wherein said lyophilizing comprises:
(a) freezing the aqueous solution at a temperature of less than −35° C.;
(b) annealing the aqueous solution at −23° C.;
(c) lowering the temperature of the aqueous solution to between −45° C. and −55° C.;
(d) annealing the aqueous solution at −33° C.; and then
(e) freeze-drying the aqueous solution.
38. The lyophilized Factor VIII composition of claim 35 in combination with a diluent.
39. The lyophilized Factor VIII composition of claim 38 , wherein the diluent is present in 2 ml.
40. The lyophilized Factor VIII composition of claim 38 , wherein the diluent is present in 5 ml.
41. A lyophilized Factor VIII composition without albumin, said composition made by lyophilizing an aqueous solution comprising:
Factor VIII;
a bulking agent comprising 2% to 6% hydroxyethyl starch;
1% to 4% of a stabilizing agent selected from the group consisting of sucrose, trehalose, raffinose, and arginine;
a calcium salt;
100 mM to 300 mM sodium chloride (NaCl); and
a buffering agent.
42. The lyophilized Factor VIII composition of claim 41 , wherein said lyophilizing comprises:
(a) (a) freezing the aqueous solution at a temperature of less than −35° C.;
(b) annealing the aqueous solution at between −30° C. and −19° C.;
(c) lowering the temperature of the aqueous solution to between −45° C. and −55° C.;
(d) annealing the aqueous solution at between −30° C. and −39° C.; and then
(e) freeze-drying the aqueous solution.
43. The lyophilized Factor VIII composition of claim 41 , wherein said lyophilizing comprises:
(a) freezing the aqueous solution at a temperature of less than −35° C.;
(b) annealing the aqueous solution at −23° C.;
(c) lowering the temperature of the aqueous solution to between −45° C. and −55° C.;
(d) annealing the aqueous solution at −33° C.; and then
(e) freeze-drying the aqueous solution.
44. The lyophilized Factor VIII composition of claim 41 , comprising about 4% hydroxyethyl starch.
45. The lyophilized Factor VIII composition of claim 41 , comprising about 200 mM sodium chloride (NaCl).
46. The lyophilized Factor VIII composition of claim 41 , wherein said stabilizing agent is present in an amount of about 2%.
47. The lyophilized Factor VIII composition of claim 41 , wherein said stabilizing agent is sucrose.
48. The lyophilized Factor VIII composition of claim 41 , wherein said stabilizing agent is arginine.
49. The lyophilized Factor VIII composition of claim 41 , wherein said stabilizing agent is trehalose.
50. The lyophilized Factor VIII composition of claim 41 , wherein said calcium salt is present in an amount of from 1 mM to 5 mM.
51. The lyophilized Factor VIII composition of claim 41 in combination with a diluent.
52. The lyophilized Factor VIII composition of claim 51 , wherein the diluent is present in 2 ml.
53. The lyophilized Factor VIII composition of claim 51 , wherein the diluent is present in 5 ml.